Sökning: WFRF:(Lopez Sendon Jose) >
Efficacy of apixaba...
-
Hohnloser, Stefan H.
(författare)
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation : insights from the ARISTOTLE trial
- Artikel/kapitelEngelska2012
Förlag, utgivningsår, omfång ...
-
2012-08-29
-
Oxford University Press (OUP),2012
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-188429
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-188429URI
-
https://doi.org/10.1093/eurheartj/ehs274DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
AimsAtrial fibrillation (AF) is common among patients with impaired renal function. Apixaban, a novel oral anticoagulant with partial renal excretion, was compared with warfarin and reduced the rate stroke, death and bleeding in the ARISTOTLE trial. We evaluated these outcomes in relation to renal function.Methods and resultsBaseline glomerular filtration rate (GFR) was estimated using the Cockcroft–Gault and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations as well as cystatin C measurements. According to baseline Cockcroft–Gault, there were 7518 patients (42%) with an estimated GFR (eGFR) of >80 mL/min, 7587 (42%) between >50 and 80 mL/min, and 3017 (15%) with an eGFR of ≤50 mL/min. The rate of cardiovascular events and bleeding was higher at impaired renal function (≤80 mL/min). Apixaban was more effective than warfarin in preventing stroke or systemic embolism and reducing mortality irrespective of renal function. These results were consistent, regardless of methods for GFR estimation. Apixaban was associated with less major bleeding events across all ranges of eGFRs. The relative risk reduction in major bleeding was greater in patients with an eGFR of ≤50 mL/min using Cockcroft–Gault {hazard ratio (HR) 0.50 [95% confidence interval (CI) 0.38–0.66], interaction P = 0.005} or CKD-EPI equations [HR 0.48 (95% CI 0.37–0.64), interaction P = 0.003].ConclusionIn patients with AF, renal impairment was associated with increased risk of cardiovascular events and bleeding. When compared with warfarin, apixaban treatment reduced the rate of stroke, death, and major bleeding, regardless of renal function. Patients with impaired renal function seemed to have the greatest reduction in major bleeding with apixaban.
Ämnesord och genrebeteckningar
-
Atrial fibrillation
-
Anticoagulation
-
Stroke prevention
-
Bleeding
-
Apixaban
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Hijazi, ZiadUppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi(Swepub:uu)ziahi940
(författare)
-
Thomas, Laine
(författare)
-
Alexander, John H.
(författare)
-
Amerena, John
(författare)
-
Hanna, Michael
(författare)
-
Keltai, Matyas
(författare)
-
Lanas, Fernando
(författare)
-
Lopes, Renato D.
(författare)
-
Lopez-Sendon, Jose
(författare)
-
Granger, Christopher B.
(författare)
-
Wallentin, LarsUppsala universitet,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)larswall
(författare)
-
Uppsala universitetUppsala kliniska forskningscentrum (UCR)
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:European Heart Journal: Oxford University Press (OUP)33:22, s. 2821-28300195-668X1522-9645
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Hohnloser, Stefa ...
-
Hijazi, Ziad
-
Thomas, Laine
-
Alexander, John ...
-
Amerena, John
-
Hanna, Michael
-
visa fler...
-
Keltai, Matyas
-
Lanas, Fernando
-
Lopes, Renato D.
-
Lopez-Sendon, Jo ...
-
Granger, Christo ...
-
Wallentin, Lars
-
visa färre...
- Artiklar i publikationen
-
European Heart J ...
- Av lärosätet
-
Uppsala universitet